B+L explores red eye relief

Bausch+Lomb has acquired a global licence to a new technology it hopes will lead to faster, more effective and longer lasting treatment for ocular redness.

The technology, licensed from biopharmaceutical firm Eye Therapies and developed in collaboration with research organisation Ora, uses a low dose of brimonidine, described as a different mechanism of action to relieve ocular redness than current products.

It was described in a phase 2 study as appearing effective in reducing ocular redness based on clinician assessment and patient reporting. Rebound vasoconstriction associated with current treatments was not observed, while the onset of action was described as rapid and long-standing.